ADMA Biologics Sued Over Revenue Inflation

ADMA Biologics was hit with a federal securities lawsuit Tuesday alleging the company inflated its revenue figures, according to a court filing. The complaint, filed in the Southern District of New York, claims ADMA misled investors about the recognition of revenue from certain contracts. The stock fell 8% on the news, trimming gains from earlier in the week.

Raymond James analyst Ryan Deschner resumed coverage of ADMA on the same day, setting a price target that implied 121% upside from the prior close. Deschner cited the company's growing pipeline of plasma-derived therapies and recent FDA approvals. He did not address the lawsuit in his note, which focused on ADMA's commercial expansion.

The split view creates a binary setup for the stock. On one side, the legal allegations could lead to financial restatements or regulatory penalties. On the other, the analyst's thesis points to strong underlying demand for ADMA's immunoglobulin products. Traders said the next catalyst is the company's response, due within 21 days of the filing. ADMA has not yet commented on the suit.

For small-cap biotech stocks, a lawsuit of this kind often amplifies volatility. The sector has seen several revenue recognition cases in recent years, and investors tend to penalize companies until the facts are clear. ADMA's case will test whether the business fundamentals can withstand legal scrutiny. The court has set an initial conference for August 15.